[Translation] Phase IV clinical trial of post-marketing safety re-evaluation of Ginkgo biloba extract injection
采用大样本、非随机、单臂、开放、多中心的研究方法,对悦康药业集团有限公司生产的银杏叶提取物注射液实施上市后安全性再评价,以考察在广泛使用条件下的预期及非预期药物不良反应。
[Translation] A large-sample, non-randomized, single-arm, open, multicenter research method was used to conduct a post-marketing safety re-evaluation of Ginkgo biloba extract injection produced by Yuekang Pharmaceutical Group Co., Ltd., in order to examine the expected and unexpected adverse drug reactions under conditions of widespread use.
100 Clinical Results associated with Indina Biotechnology (Shanghai) Co., Ltd.
0 Patents (Medical) associated with Indina Biotechnology (Shanghai) Co., Ltd.
100 Deals associated with Indina Biotechnology (Shanghai) Co., Ltd.
100 Translational Medicine associated with Indina Biotechnology (Shanghai) Co., Ltd.